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Abstract
Background: The goal of medical research is to develop interventions that are in some sense superior, with respect
to patient outcome, to interventions currently in use. Similarly, the goal of research in methodological computational
statistics is to develop data analysis tools that are themselves superior to the existing tools. The methodology of the
evaluation of medical interventions continues to be discussed extensively in the literature and it is now well accepted
that medicine should be at least partly “evidence-based”. Although we statisticians are convinced of the importance
of unbiased, well-thought-out study designs and evidence-based approaches in the context of clinical research, we
tend to ignore these principles when designing our own studies for evaluating statistical methods in the context of
our methodological research.
Main message: In this paper, we draw an analogy between clinical trials and real-data-based benchmarking
experiments in methodological statistical science, with datasets playing the role of patients and methods playing the
role of medical interventions. Through this analogy, we suggest directions for improvement in the design and
interpretation of studies which use real data to evaluate statistical methods, in particular with respect to dataset
inclusion criteria and the reduction of various forms of bias. More generally, we discuss the concept of “evidence-based”
statistical research, its limitations and its impact on the design and interpretation of real-data-based benchmark
experiments.
Conclusion: We suggest that benchmark studies—a method of assessment of statistical methods using real-world
datasets—might benefit from adopting (some) concepts from evidence-based medicine towards the goal of more
evidence-based statistical research.
Keywords: Method evaluation, Good practice, Comparison study, Clinical trial
Background
The role of a medical practitioner is to perform interven-
tions on patients that are as beneficial as possible in a
broad sense, taking into account both the short term and
the long term, health outcomes, quality of life and often
other aspects, such as ease of use or extended applica-
tion to a wider set of indications. In contrast, it is the goal
of medical researchers to develop new interventions that
are superior—or non-inferior with fewer side effects—to
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those already in existence. Rightfully, the unbiased sys-
tematic evaluation of the new and previously existing
interventions is considered crucial by the medical com-
munity and is a focal point of medical literature. The
concept of “evidence-based medicine” (EBM) has been
receiving growing attention and credibility for decades.
We can draw a parallel between medicine and computa-
tional statistics, with the statistical consultant analogous
to the medical practitioner and the applied statistical
researcher to the medical researcher. See Table 1 for an
overview of this analogy that will be developed through-
out the paper. The role of a statistical consultant is to
analyze the client’s data such that the results help to
answer a research question as completely as possible,
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Table 1 Analogy between clinical research and computational statistical research
Clinical research Computational statistical research
Trial type In vitro/animal study Simulation
Clinical trial Benchmark study
Blinded Neutral and blind analysis
(Placebo) controlled (Null-model) controlled
Cross-over Paired samples
Multi-arm Multiple methods
Investigators Trialist Researcher conducting benchmark experiment
Medical researcher Methodological researcher in computational statistics
Sponsor Methodological researcher in computational statistics
Observation unit Clinical trial patients Real datasets
Comparators Therapies, interventions and controls Statistical and machine learning methods
Problem Treatment of medical condition Answering a question using data, e.g. prediction problem
Context Patient’s preference, social context Substantive context
Personalized medicine Meta-learning
Objectives Improving patient’s health Yielding reliable answer, e.g. increasing prediction perfor-
mance
Selecting and applying therapy to patient Selecting and applying methods to datasets
Application by medical practitioner Application by statistical practitioner/consultant
Endpoints Relevant clinical endpoints Error rate, AUC, computing time, etc.
Missing value (e.g. dropout) Failure to produce output
uncovering and approximating a truth that is assumed
to exist behind this question. Once more, there may be
other considerations, such as cost and computation time.
The goal of applied statistical researchers is to develop
data analysis methods and tools that are, again, in some
sense superior to those already in existence. However,
here the parallel between medicine and computational
statistics ends, as the unbiased evaluation of these new
statistical methods and tools in real-data settings, includ-
ing their comparison to existing methods, is given usually
only poor attention in the literature. In this paper, we
explore the disparity between evidence-based medicine
and “evidence-based computational statistics” by exam-
ining the state of methodological aspects of benchmark
studies, the systematic comparison of statistical methods
using real datasets.
Greenhalgh et al. [1] state: “It is more than 20 years since
the evidence based medicine working group announced
a “new paradigm” for teaching and practicing clinical
medicine. Tradition, anecdote, and theoretical reasoning
from basic sciences would be replaced by evidence from
high quality randomized controlled trials and observa-
tional studies, in combination with clinical expertise and
the needs and wishes of patients.” Our aim is to start
a discussion on “evidence-based” data analysis in which
“tradition, anecdote, and theoretical reasoning from
basic sciences [including simulations] would be [com-
plemented] by evidence from high-quality [benchmark
studies], in combination with [statistical] expertise and
the needs and wishes of the [substantive scientists]”. Our
discussion is based on an analogy between clinical trials,
which play a crucial role in evidence-based medicine, and
real-data-based benchmarking experiments in method-
ological statistical science, with datasets playing the role
of patients and methods playing the role of medical inter-
ventions (see Table 1).
In computational statistics, “evidence” can be generated
through theoretical considerations (e.g., the proof that an
algorithm converges or the asymptotic relative efficiency
of a test), by simulations (i.e., with artificial datasets ran-
domly drawn from a particular distribution) or through
real-data examples. However, theory is often of little help
in highly complex real-world situations, since it usually
requires unrealistic simplifying assumptions regarding the
data structure. In this paper we focus on the role of real-
data analysis (as opposed to simulations) and the design
of such studies. This type of evidence can be seen as
“empirical evidence”.
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In a specific example of the greater incorporation of
evidence in evaluating and presenting statistical method-
ology, the recently established STRATOS (STRengthening
Analytical Thinking for Observational Studies) coopera-
tion [2] aims at providing guidance regarding the choice
of statistical method based on empirical evidence and
experts’ experience in the context of observational stud-
ies in medical research. However, such groundbreaking
projects are still in their infancy and the concept of evi-
dence and the role of real data in this context are not yet
well defined.
In machine learning—a field focused on prediction as
opposed to explanation—ideas relating to evidence from
real data are becoming commonplace. Systematic compar-
ison studies, often denoted benchmark experiments, based
on real data are a core of the literature, their realizations
made substantially easier through the use of databases
of datasets available for benchmarking, such as the UC
Irvine (UCI) machine learning repository [3] and the
OpenML platform [4]. Machine learning challenges [5],
which can be seen as collective benchmarking studies,
are also receiving substantial attention from the commu-
nity. Machine learning scientists work to obtain empirical
evidence on the performance of algorithms (often algo-
rithms to construct prediction models) on real datasets
in analogy to medical doctors obtaining empirical evi-
dence on the performance of therapies on human patients
(see Table 1). Machine learning scientists are further
aware of the no-free-lunch theorem (i.e., that no algo-
rithm works best in all situations) and again address this
problem through evidence-based research, by evaluating
which algorithm performs best in which situations and
even automatizing this process—a task known as meta-
learning.
We statisticians are in general reluctant to adopt the
concept of evidence-based decision-making: that the
choice of statistical method to use in a given situation
should be guided primarily by “evidence” in general and
empirical evidence more specifically. This reluctance is
also strong in the context of prediction modelling, which
lies in the domains of both statistics and machine learn-
ing and has long been addressed by machine learners in
benchmark experiments. Some statisticians feel a more
evidence-based approach implies the jettisoning of the
experience of the statistical consultant in favor of a sus-
pect set of guidelines inspired by oversimplification. The
idea that the choice of a method may be reached in a more
or less automatic manner makes us feel unwell. Statisti-
cians often argue that no ruleset or guideline can replace
the judgement of an expert statistician, nor can a rule-
set take into account all aspects of a problem, such as
the substantive context. Interestingly, these are exactly
the types of arguments invoked by EBM-sceptics. Medical
doctors questioning EBM argue that an evidence-based
approach based on systematic rules cannot cope with
the complexity of individual cases—e.g., with respect to
multi-morbidity—and, again, ignores important consid-
erations, such as the wishes and social backgrounds of
patients.
The existence of specific datasets (in statistics) or
patients (in medicine) with complexity that cannot be
accommodated by simple evidence-based rules may be
seen as an argument in favor of the need for more evi-
dence, i.e. evidence tailored to particular dataset or patient
profiles. This need has long been acknowledged in med-
ical research and is being addressed in the emergence of
personalized/individualized medicine, with subgroup and
interaction effect analyses in clinical trials being simple
steps in this direction. Similarly, in computational sci-
ences, the development and use of meta-learning are steps
towards tailored algorithms.
Medical doctors or statisticians may still maintain that
even the best and most individualized evidence cannot
replace expert intuition, nor adequately take into account
the specific context of the choice. This is a controversial
issue. One may argue that an expert’s intuition is sim-
ply the result of the unconscious collection of evidence
from personal experience during a career, and that such
evidence could also be formalized as systematic rules. If
so, the question becomes whether one can trust machines
to derive rules as reliably as the brain of an expert, and
whether this can be achieved in practice considering the
current state-of-the-art of computational sciences. In a
given situation, the amount of information (e.g., number
of cases) and the source of the information (e.g., type and
quality of studies and data) play further crucial roles in this
appraisal.
Statisticians may also contend that the need for empir-
ical evidence in statistics is not as strong as in medicine,
as theoretically one can subject a dataset to as many sta-
tistical methods as one desires, while the same cannot be
said for patients and interventions. Clearly, it does not
harm a dataset to undergo different statistical analyses,
but it may harm patients to undergo different interven-
tions before identifying the most appropriate. While the
sense of this argument is evident, it is well known that
the approach of performing a large number of statis-
tical methods on a dataset and deciding which one is
the “right one” based on the results may yield substan-
tial problems relating to the idea of “fishing for signifi-
cance” [6]. An illustration is provided in an experiment in
which they asked 29 statisticians to analyze a dataset with
the goal of assessing the potential correlation between
skin color of football players and red cards [7]. Perhaps
surprisingly to some, but likely not to many statisti-
cians, the researchers obtained very different—and partly
contradictory—answers! Which result should be reported
as definitive? Researchers are obviously tempted to report
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that which is most fitting to their goals. Due to multi-
ple comparison effects, this strategy is likely to yield false
research findings that are simply the result of optimiza-
tion and data dredging and would fail to be validated using
independent data [6, 8].
When considering types of evidence, statisticians are
usually keener to evaluate their methods using data simu-
lated from known distributions as opposed to conducting
benchmark studies consisting of a large number of real
datasets. The use of simulations as opposed to real-data
analysis can be considered analogous to using in vitro
studies or animal trials as opposed to patient-based exper-
iments: one can control important factors—genotypes,
age, diet, etc. in medicine; the dataset size, the signal
strength, etc. in computational science—and thus obtain
homogeneous groups and “know the truth”. In the context
of, say, hypothesis testing or the estimation of a vari-
able’s effect for the purpose of explanation (as opposed
to prediction), the truth is unknown in real data, thus
making simulations indispensable for evaluating how well
statistical methods uncover the truth. Moreover, one can
simulate as much data as computationally feasible, allow-
ing reliable systematic evaluation of the methods in the
considered simulation settings. In many situations, sim-
ulations are indispensable. However, even with the best
simulations, one would often remain uncertain as to the
performance of the examined methods in the much more
complex real world.
In this context, we would like to start and fuel a discus-
sion on the appropriate design of real-data studies yielding
evidence in statistical research, always with careful con-
sideration of a dataset’s specificities/substantive context
and without discarding expert intuition and simulations.
In analogy to EBM and the choice of therapies, large-scale
benchmarking research in statistics may yield tentative
rulesets and guidelines to facilitate the choice of data anal-
ysis methods without dictating them. We would like to
discuss the question—without claiming to have the ulti-
mate answers—of the role of EBM-inspired concepts in
real-data benchmark analysis in computational applied
statistics.
In this paper, we assume that the performance of a
statistical method on a real dataset can be objectively
assessed using some criterion. This is the case, for exam-
ple, for prediction methods: natural criteria are error
measures such as the error rate (in the case of binary
classification) or the Brier score (in the case of survival
prediction), which can be estimated through the use of
resampling techniques such as cross-validation. This is the
context we will use to explain our ideas. Methods whose
performance on real datasets cannot be quantified using
real data, such as hypothesis tests or effect estimation pro-
cedures, are not considered here. Moreover, unless stated
otherwise we assume that a method is well defined and
runs automatically on a dataset without human interven-
tion such as parameter initialization or preprocessing. The
issue of human intervention is discussed further in “Role
of the user” section.
While one cannot incorporate all aspects of EBM into
the context of the evaluation of statistical methods using
benchmarking, we claim that some precepts commonly
accepted in EBM may be helpful in defining a concept of
“evidence-based computational science”. A simple exam-
ple is that of sample size, an extensively researched ques-
tion on the number of patients required in a clinical trial
in order to make valid statistical claims on any result.
Analogously, in benchmarking, in order to draw conclu-
sions from real-data analysis beyond illustrative anecdotic
statements, it is important to have considered an ade-
quate number of datasets; see Boulesteix et al. [9] for a
discussion on the precise meaning of “an adequate num-
ber”. In the remainder of this paper, we discuss further
concepts essential to formulating evidence-based state-
ments in computational research using real datasets. After
the presentation of a motivating example in “Motivating
example” section, the significant question of the definition of
selection criteria for datasets is addressed in “Selecting
datasets: a major challenge” section, while other con-
cepts from medical sciences such as analysis proto-
cols, placebos, evidence levels, and bias are discussed in
“Further EBM-related concepts” section (see Table 2 for
an overview of these concepts).
Motivating example
Since the early 2000s, numerous supervised classification
algorithms have been proposed in the bioinformatics and
statistics literature to handle the so-called n  p problem,
i.e. the case where the number p of candidate covari-
ates (for example, gene expression data collected using
microarray technology) by far exceeds the number n of
patients in the dataset. Common approaches to handle
this dimensionality problem include preliminary variable
selection, dimension reduction, penalized regression or
methods borrowed from machine learning [10].
In this setting, the comparison of existing classifica-
tion methods using real microarray datasets has been the
topic of a number of papers [11–18], which do not aim
at demonstrating the superiority of a new method pro-
posed by the authors: they consider only existingmethods,
thus implying a certain level of neutrality [19]. Most of
these papers consider measures such as the error rate or
the area under the curve to assess the performances of
the classification methods. For each considered perfor-
mance measure, the results are essentially presented in
the paper as an N × M table, where N is the number of
considered real datasets and M is the number of consid-
ered methods. The number M of methods varies across
papers and ranges between M = 2 and M = 9. These
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Table 2 Some ideas for the improvement of benchmarking practice
Clinical research Treated in Transfer into computational Example(s)
statistical research?
Sample size calculation [9] Possible and desirable [9] [35]
Strict inclusion criteria Sec. 3 Possible and desirable [20, 21, 35]
Trial protocol Sec. 4.1 Principle might be helpful in adapted form
Quality control Sec. 4.2 Principle might be helpful in adapted form
e.g. via platforms like OpenML [4]
Placebo/reference Sec. 4.3 Principle might be helpful in adapted form
Blinding Sec. 4.4.1 Principle might be helpful in adapted form
Intention-to-treat Sec. 4.4.2 Adequate treatment and reporting of [29]
missing values: possible and desirable
Levels of evidence Sec. 4.5 Principle might be helpful in adapted form
methods are sometimes combined with different vari-
able selection or dimension reduction techniques, thus
yielding a higher number of investigated method vari-
ants. Considered methods vary across papers and include,
for example, discriminant analysis, tree-based methods,
nearest neighbors, or support vector machines.
We feel that these studies contain major flaws if exam-
ined in the light of the principles of clinical research. First
of all, most are underpowered: with the exception of the
study by de Souza et al. [18] (N = 65 datasets) and that of
Statnikov et al. [17] (N = 22 datasets), they use between
N = 2 and N = 11 datasets to compare the methods,
too few to achieve reasonable power when comparing the
performances of classification methods [9]. Following the
sample size calculation approach outlined in Boulesteix
et al. [9], the required number of datasets to detect a dif-
ference in error rates between two methods of, say, 3%
with a paired sample t-test at a significance level of 0.05
and a power of 80% is as high as N = 43 if the standard
deviation (over the datasets) of the difference in error rates
is 7%—a standard deviation common in this setting [9].
Furthermore, it is not clear how the datasets included
in the studies were selected. No clear search strategy or
inclusion criteria are described in the papers. Some of
the datasets are used in several studies and sometimes
denoted “benchmark datasets”, but none are used in all
studies. The problem of the selection of datasets for inclu-
sion in a benchmark study will be further discussed in
“Selecting datasets: amajor challenge” section. It is further
unclear whether datasets have been eliminated from the
study after having been originally included, since this task
is not documented. We will come back to this problem in
“Non-compliance and missing values” section.
Regarding neutrality, even if the aims of these stud-
ies are not to demonstrate the superiority of a particu-
lar “favorite” new method, authors are sometimes likely
to have preferences for or better competence in one or
several methods compared to the other(s). For example,
one of the authors’ team may have a very strong back-
ground in a particular classification method, support vec-
tor machines, as suggested by their publication records.
They are then likely to be more proficient users of this
method than of the other(s) (although we can admittedly
not verify this conjecture!), which may induce bias, as
further discussed in “Neutrality and blinding” section.
Selecting datasets: a major challenge
The difficulty in sampling datasets
In the context of a clinical trial the population of interest
is the population of patients with (or at risk for) a particu-
lar health condition who may benefit from the considered
therapies. Diseased patients usually seek medical help,
making it possible to draw from this population. For non-
diseased patients (who may benefit from interventions
such as prevention programs), representative sampling
methods exist. On the whole, even if sampling is often a
challenge and there remains the risk of bias, it is normally
feasible to obtain reasonably representative samples from
the population of interest.
In the context of benchmarking, the “population of
interest” is the population of datasets in the focused
research field whose structure and properties would allow
them to be the target of the considered data analysis
methods. In practice there are no simple sampling proce-
dures for this population for a variety of reasons. Firstly,
datasets are not typically systematically registered, except
perhaps in specific fields (for example, most microar-
ray datasets as considered in our illustrative example in
“Motivating example” section are nowadaysmade publicly
available via dedicated platforms). Secondly, the differ-
ent approaches to access datasets (repositories, software
packages, additional files or companion websites of pub-
lished papers, personal contact with data owner) are all
selective: they do not allow the drawing of indepen-
dent datasets from the population of datasets. Thirdly, a
“dataset” is not as well defined as a “patient” because it
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may be split, merged, preprocessed, etc. This is often the
case in the context of microarray studies such as those
considered in “Motivating example” section. These prob-
lems must be kept in mind when statistically interpreting
the results of benchmarking, results which should be seen
as conditional—given the data source (e.g., a particular
data repository)—rather than as proper inference for a
population.
Beyond these issues related to the sampling of datasets,
an additional difficulty is related to the knowledge of the
researcher conducting the benchmark experiment regard-
ing the substantive context of the datasets. In some cases a
profound knowledge of the substantive context is particu-
larly important in conducting correct statistical analyses.
One may then want to collect only datasets which are
particularly well documented or datasets from one’s field
of interest, an additional constraint which complicates
the sampling procedure, reduces the number of potential
datasets and may introduce a bias.
Which patients to analyze in clinical trials, which datasets
to analyze in benchmarking studies: a short overview of
the common handling of inclusion/exclusion criteria
For clinical trials, strict criteria are applied when selecting
patients to include in the study, with all patients fulfill-
ing these criteria enrolled until a predefined sample size is
reached. In contrast, for benchmarking studies in compu-
tational literature the criteria used for selecting datasets
are most often non-transparent, with a few exceptions in
the field of statistics formicroarray data such as those con-
sidered in “Motivating example” section [20] and machine
learning [21]. The consent of the data owner to make
a dataset available is necessary but is often given infor-
mally. The minimum number of datasets to be included
is usually not determined. Though conscious attempts to
misrepresent the results (“cheating”) are probably rare,
questionable elimination of datasets may be performed
by honest researchers based on a posteriori, i.e. after
seeing the results, plausible explanations such as, “the
method did not work well on this dataset because it
has property X, so it is justified to exclude it”, although
this property—now presented as important—was not
identified as an exclusion criterion beforehand. Such a
posteriori elimination may lead to substantially biased
results [22].
A related concern in the clinical field is the potential for
the subsequent elimination from the study or change in
treatment of a once-enrolled patient, a topic taken very
seriously from a quality and analysis point of view and one
highly studied in the literature. The handling of patients
enrolled but failing to comply to treatment and the analo-
gous situation of datasets producing nonsensical or miss-
ing results in real-data benchmark studies is discussed in
“Non-compliance and missing values” section.
Adopting principles from clinical research into
benchmarking
We claim that strictly defined inclusion criteria could be
applied when selecting datasets for inclusion in a bench-
mark study and that reasons for post-hoc exclusion should
be reported thoroughly, for example, using flowcharts in
the spirit of the CONSORT statement [23], a guide on
the transparent reporting of trials. Inclusion criteria for
datasets may be, for example, “the number of observations
lies within a given range”, “the number of covariates lies
within a given range”, “the scales of the covariates are of
a certain kind”, “the outcome is applicable to the analy-
sis of interest”—regression, classification, time-to-event,
etc.—or requirements on the number of missing values.
There are three primary motivations for defining inclu-
sion criteria, i.e. excluding datasets. Firstly, one typically
excludes datasets which would render the assessment of
performance of the statistical method difficult: for exam-
ple, one may exclude small datasets because error estima-
tion (e.g., with cross-validation) would be highly variable
(a common issue in the context of the gene expression
data considered in “Motivating example” section), or large
datasets because the analysis would be too computa-
tionally demanding. This is similar to, for example, the
exclusion of incontinent patients from a clinical trial if the
outcome of interest is the result of a 24 h urine test. Sec-
ondly, a dataset may be excluded due to low data quality,
for example, if the number of evident input data errors
and the number of missing values are too great to yield
proper analysis. Thirdly, one excludes datasets to focus
on a particular setting and reduce heterogeneity for easier
interpretation of the results; for example, in the context of
gene expression one may decide to include only datasets
measured with a particular type of microarray. These
reasons for the exclusion of datasets contribute to the con-
ditional character of results emerging from a benchmark
study, as exclusion criteria do to the results of clinical tri-
als. In both settings, there is a strong need for the precise
reporting of inclusion criteria to enable fair appraisal of
the corresponding findings.
A fourth reason—tightly related to the third—
particularly affects benchmark studies undertaken in
articles which are introducing a new statistical method:
authors may exclude datasets because they have charac-
teristics that are expected to lead to the demonstration
of the inferiority of the new method. This exclusion of
datasets may be a result of fear of publication bias, a
topic of abundant literature in medical sciences, and
also of concern in computational sciences [24]. The
researchers may rightly worry that studies suggesting
better performance of a new method are more likely to
get published than studies suggesting equal or worse
performance. However, in some cases there are legitimate
reasons to exclude datasets that would be troublesome
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for the new method. If so, it should be clearly stated—
understandable even to non-experts—that the inclusion
criteria are defined so that the new method will achieve
better performance and that the conclusions drawn from
the benchmark study are then only valid for datasets
satisfying these criteria. As with clinical trials, the inclu-
sion criteria should not be tuned a posteriori to improve
apparent performance of any given method. Finally, we
point out that a conscious selection of promising datasets
is not always sensible: it may indeed be interesting to
also assess performance on datasets for which the new
method does not perform as well in order to better
delimit its appropriate field of application.
Further EBM-related concepts
This section discusses further EBM-related concepts from
clinical research and their possible adaptation to the con-
text of computational statistical research; see Table 2 for
an overview.
Registration and protocols
In clinical trials, study protocols are written before the
start of the trial to ensure the quality of the study and to fix
decisions on some of the aforementioned issues, such as
sample size, inclusion and exclusion criteria, study design,
analysis methods, definitions of subgroups, the handling
of missing values, methods to protect against bias and pre-
sentation and judgement of results. Deviations from the
protocol decided at a later time or procedures that are fol-
lowed but were not described in the protocol damage the
quality of a study, even if not left unexplained. For exam-
ple, a change of the primary endpoint, i.e. of the main
research question focused on in a trial, draws the validity
of findings into question. This is also a matter of concern
in benchmark studies when several performance mea-
sures, such as estimates on the method’s prediction error,
accuracy or computation time, are investigated. False-
positive findings and biased results can be avoided when
one of the measures is declared the primary endpoint
before analysis. Registration of a trial in a registry for pub-
lic availability [25] is another option to improve quality
control of the clinical trial. Although information pro-
vided in this way is not as detailed as in a study protocol it
is at least informative on the initial study goals.
More recently, the journal Cortex launched a new
innovation in scientific publishing called a “Registered
Report” [26]. The principle is to split the review process
into two stages. Initially, experimental methods and pro-
posed analyses are pre-registered and reviewed prior to
data collection. Following peer review, positively evalu-
ated proposals are offered “in-principle acceptance”. The
authors then proceed to conduct the study while adhering
to the registered report. After a second peer review by the
same panel, the final manuscript is published regardless of
the results, i.e. no matter whether the results are signifi-
cant or not [26]. Since 2013 this concept has been adopted
by various journals from different scientific fields.
Registration of a study and adherence to a protocol
are concepts that may be partly transferable to bench-
mark studies and might help prevent or decrease both
the fishing for significance problems [27] and publica-
tion bias [24]. The OpenML platform [4] provides these
possibilities in the field of machine learning. Study reg-
istration or use of a protocol in computational sciences
would, among other benefits, help to avoid the unjusti-
fied exclusion of methods or datasets from a benchmark
study or the a posteriori fine-tuning of model parame-
ters performed for presentation of favorable but biased
results.
Quality control
Quality control has been developed in EBM to prevent
erroneous execution of a trial, faulty data generation and
incomplete or incorrect reporting, where proper report-
ing also includes proper reporting of statistical analysis.
For example, it is stated in the Guideline E6 of the Inter-
national Council for Harmonisation of Technical Require-
ments for Pharmaceuticals for Human Use (ICH) that “the
sponsor is responsible for implementing and maintaining
quality assurance and quality control systems with writ-
ten ’StandardOperating Procedures’ (SOPs) to ensure that
trials are conducted and data are generated, documented
(recorded), and reported in compliance with the proto-
col [. . .]” and that “quality control should be applied to
each stage of data handling to ensure that all data are reli-
able and have been processed correctly”. It is evident that
the reliability of data and a quality controlled handling of
data are not of minor importance in benchmark studies.
“Quality control systems” such as monitoring and SOPs
might be partly transferable to the context of benchmark
studies, where the role of the sponsor may be taken over
by a methodological researcher involved in the planning
but not in the carrying out of the benchmark study (see
Table 1). Again, exchange platforms such as OpenML [4]
could be useful for this purpose.
Placebos
A benchmark study conducted to compare the perfor-
mances of two or more prediction models can be equated
to a multi-arm clinical trial. When no standard therapy
exists to which the new experimental treatment can be
contrasted in a clinical trial, the trial is often placebo
controlled. In the same manner, a benchmark study on
the performance of competing prediction models could
be “placebo controlled” by including in the comparison a
method that, by design, performs no better than chance.
For example, in a dataset where the outcome is a rare event
with a prevalence of 5%, a reference method could be a
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naive classifier that always votes for the majority class,
thus achieving a misclassification rate of only 5%. A useful
predictionmodel would have to be able to outperform this
reference method. In this specific example the necessary
level of the performance of the reference method is obvi-
ous, but in more complex cases the control method would
have to be designed carefully.
Bias
Neutrality and blinding
According to Boulesteix et al. [19], a benchmark study
can be considered neutral if (A) the main focus of the
article is the comparison itself, which implies that the pri-
mary goal of the article is not to introduce a promising
new method; (B) the authors are reasonably neutral; (C)
the evaluation criteria, methods, and datasets should be
chosen in a rational way. Requirement (B) means that the
authors of a neutral comparison study do not have a pref-
erence for any particular method and, further, that they
are (at least as a collective) approximately equally expe-
rienced with each of the considered methods. However,
these requirements are very difficult to fulfill in practice,
even if there exist positive exceptions; see for exam-
ple the comparison study between splines and fractional
polynomials [28] co-authored by experts of these two
approaches.
In practice, researchers performing comparison stud-
ies often expect or hope for good results for a particular
method—for example because they are those who devel-
oped it in previous research—thus perhaps consciously
or unconsciously favoring it in a variety of possible ways.
We conjecture that such mechanisms were at work in
some of the studies discussed in “Motivating example”
section, even if they were originally intended as neutral.
In analogy to the biased assessment in the clinical context,
researchers conducting benchmarkingmay select datasets
or performance measures that are likely to yield good
results for a “preferred” method. Similarly to differential
patient care, researchers may perform parameter tuning
more carefully, or fix bugs more eagerly, for a preferred
method. Biases may also be a hazard even when a study
is intended as neutral, i.e. does not aim to demonstrate
the superiority of a particular method. And although it
is well known that a new intervention must compete
against the current standard of care in clinical trials, such a
practice is not widespread in the context of comparison
of statistical methods. Though it does not introduce bias
in the strict sense, the selection of weak competitors in a
benchmarking study might lead to an exaggeration of the
superiority or advantages of, again, a preferred method.
In a few words, failure to fulfill requirement (B) may
produce bias.
To avoid this bias, strategies inspired from blinding
for clinical trials might be imagined. In clinical settings,
blinding (meaning that the patient and—in case of double-
blinding—the caregivers and persons evaluating the end-
point are unaware of to which study group the patient
belongs) is effective in helping to avoid several sources
of bias in clinical trials. For example, to ensure unbiased
assessment of a patient’s primary endpoint, a trial may be
observer blind, i.e. endpoint assessment is performed by a
person who does not know how the patients were treated.
Medical staff can also be blinded to ensure no differential
care of the patients. The feasibility of blinding strategies
in the context of statistical research obviously depends on
the characteristics of a specific study. In the rest of this
section, we give first suggestions on how to use blind-
ing strategies for improving neutrality in benchmarking
studies.
We use the concept of “unexpectedly bad results” as an
example. An unexpectedly bad result suggests that some-
thing went wrong with the considered method and that
there may be an error somewhere. In analogy to blinding
in clinical trials, we suggest that the handling of such prob-
lems might initially be conducted blindly, i.e. the decision
to look for bugs or not should be taken without know-
ing which method yielded the unexpectedly bad result,
in analogy to the blinding of medical staff. To implement
this idea one might for example label the methods with
non-informative names such as A, B, C, etc., withholding
method-specific error messages from the debuggers and
not unmasking the methods until the end of the study.
Similarly, researchers could be blinded to the data through
forbidding inspection of datasets that yield “unexpected
results”, thus reducing the ability to exclude datasets—or
fine-tune a method—in order to achieve better results a
posteriori. Although one might perform the data inspec-
tion at a later point, the suggested blinding procedure
would imply that this later inspection would not affect the
reporting of the main benchmarking results.
More generally and beyond the strict concept of blind-
ing, some decisions on study design, such as the selection
of competing methods or performance measures, may
be (partly) delegated to neutral persons if the principal
investigators are not neutral themselves. The definition
of strict inclusion criteria and the use of collaborative
platforms such as OpenML [4] to systematically extract
datasets satisfying these criteria, thus automatizing the
benchmarking process, are also measures to counteract
the effect of non-neutrality with regard to selection of
datasets.
Non-compliance andmissing values
In clinical trials, all enrolled patients are included in the
statistical analysis: no patients are eliminated due to their
outcome and the handling of patients who fail to com-
ply to the treatment of the study arm in which they
were included is delicate. More generally, the handling
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of missing values is considered crucial, and is given a
great deal of attention in the literature. In particular,
the intention-to-treat analysis strategy stipulates that all
patients randomized in a clinical trial should be analyzed
according to the initial randomization. Arbitrary exclu-
sion from analysis or systematic drop-out can lead to
severe bias.
In contrast to medical sciences, the issue of missing val-
ues has been given poor attention in the computational lit-
erature. Missing values may occur for different reasons in
the context of benchmarking. For example, values may be
missing “by design”, because a particular method was not
applicable to a particular dataset. In this case, the bench-
marking results should be analyzed and interpreted while
taking these design issues into account. Missing values
may also occur “accidentally”, because amethod unexpect-
edly failed to produce a result for a dataset, for example,
due to the non-convergence of the fitting process.
Similarly to the principle of intention-to-treat analy-
ses in clinical research, all datasets originally included
in a benchmark study would ideally remain for analysis,
where appropriate treatment of these accidental miss-
ing values has to be defined depending on context. See
Bischl et al. [29] for one of the few papers we are aware
of explicitly stating how the missing values are handled.
For example, if a method does not output a meaningful
result for a considered dataset, one may set the perfor-
mance of this method to the performance of the reference
(when such a reference exists) or to the performance of the
worst method (which makes sense only if more than two
methods are compared). Post-hoc exclusion needs to be
avoided and might only be acceptable if exclusion strate-
gies are established beforehand and if based on decisions
from a blinded review of results.
Role of the user
An important aspect we have not yet discussed is the role
of the user in a benchmark experiment. In this paper,
we have assumed that a method is well defined and runs
automatically on the datasets without human intervention
such as parameter initialization or preprocessing. This
may hold true for some methods, such as a classification
method without parameters or with parameters that can
be efficiently tuned by cross-validation, but not for all.
Similar issues may affect clinical trials. The counterpart
of a method running without human intervention would
be, for example, a drug that is produced and administered
to the patients in a standardized way, so that the medical
staff caring for the patient have no influence on the pro-
cess. Obviously in the case of interventions in the form
of, e.g., surgery, physiotherapy or psychotherapy, human
factors can affect the quality of the intervention.
In the context of benchmarking for the evaluation of
classification methods, Duin [30] distinguishes between
studies comparing classifiers running without user inter-
vention and studies comparing classifiers necessitat-
ing human intervention. In the latter case, Duin [30]
again differentiates between benchmark experiments
evaluating methods as used by a handful of expert users—
experiments meant to yield the most reliable informa-
tion on the method’s performance in optimal conditions,
the only way to obtain a picture of the maximal poten-
tial of the method—and those involving “arbitrary users”
(whereby the results of a method could be averaged over
the users). In practice, however, this differentiation is
rarely addressed in benchmarking literature. Complexi-
ties involving users could be seen as an argument against
benchmarking in general, or in favor of extended bench-
marking with the user considered as a factor. In the
following we briefly sketch different scenarios regarding
the expertise of the user in cases where methods require
human intervention.
In the clinical context, it is obvious that the levels of
expertise of the staffs conducting the compared interven-
tions should be as equal as possible. For instance, if one
intervention is conducted by experienced leading experts
only and another intervention is conducted by young resi-
dent physicians only, the direct comparison will be biased.
Similarly, in benchmarking, if an expert of method A uses
both method A and a method B he/she is not familiar
with, the comparison between methods A and B would
be flawed. If there are no scientists with expertise in both
methods A and B, a solution could be to involve several
experts, each running only the method in which he/she
is an expert. However, it is then impossible to distinguish
between the effect of the method and the individual effect
of the expert. To allow this distinction, the experts would
have to also run the methods with which they are less
familiar—an ethically controversial idea in clinical settings
but possible in the context of benchmarking. In any case,
the results of this type of benchmarking study should be
seen as conditional on the involved experts. To elimi-
nate this conditional character, one would have to draw a
sample of experts, a difficult task in practice.
It may however also be interesting to get a picture of the
performance of methods in standard settings, i.e. those
involving arbitrary users without expertise in the consid-
ered methods. Although the results of the benchmarking
study would be again conditional on the users, consider-
ing a sample of arbitrary users would address this issue.
Finally, note that the performance difference between the
methods that is estimated in this setting would not neces-
sarily be equal to the performance difference when experts
are involved, as methods do not necessarily suffer equally
from the lack of experience of their users.
These ideas are certainly difficult to implement in prac-
tice, but potential precedence exists. In the machine
learning field initiatives such as the aforementioned
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collaborative platform OpenML [4], which collects and
stores the results of benchmarking experiments per-
formed by a large number of researchers featuring users
of various levels of expertise, may provide a technical
framework to address user-related issues.
Levels of evidence
Suggestions on “levels of evidence” have been made in
the literature to aid in the assessment of the quality of
information derived from clinical studies; see the report
of the Canadian Task Force on the Periodic Health Exam-
ination for an early seminal work [31]. These suggestions
present a rough rating scale in which systematic reviews
and meta-analyses provide the highest level of evidence,
followed by high quality randomized controlled trials,
cohort studies, case-control studies and finally, expert
opinions. The quality of benchmark studies could be, in
principle, rated in a similar way. Figure 1 suggests ideas
for a possible classification system. Much of the sys-
tem is shaped by the concept of neutrality, whether a
paper is introducing a new statistical method or there is
otherwise a “preferred” method, whether consciously or
subconsciously.
Fig. 1 Evidence pyramid. Suggested levels of evidence for results of
benchmark studies designed for the comparison of statistical
methods using real data. A neutral study is conducted by researchers
that do not have a preference for any particular method and are (at
least as a collective) approximately equally experienced with each of
the considered methods. A non-neutral study is one in which the
researchers have a potential conscious or subconscious interest in the
demonstration of the superiority of a given method (the “preferred
method”) or have greater experience in one or more of the methods
(again, the “preferred method”) to the extent that it may bias the
results. A non-preferred method is a statistical method from a
non-neutral study but not that or those method(s) thought to be
preferred. Bias innon-neutral studies can advantage preferred methods
and disadvantage non-preferred methods, or both
As stated earlier, when a comparison study is presented
in a paper that introduces a new method, results tend to
be biased in favor of the new proposal [32]; moreover,
the competing methods often show comparatively bad
performance, as they have consciously or unconsciously
been put in an inferior position (e.g., through suboptimal
parameter settings or failure to fix bugs). As such, results
related to the introduction of new methods rank consis-
tently lower on the hierarchy. Similarly, when neutrality
is affected through differential expertise in the exam-
ined methods, the quality of the results again suffers. In
general, bias in non-neutral studies can advantage pre-
ferred methods and disadvantage non-preferred methods,
or both.
Starting at the highest level, like on the EBM scale,
meta-analyses and systematic reviews occupy the highest
position, although in the context of computational science
these studies are still in their infancy and not straight-
forward methodologically [33, 34]. Specifically, to achieve
the highest level of evidence, these meta-analyses and sys-
tematic reviews must be based on high quality neutral
comparison studies [19]. The neutral comparison stud-
ies themselves are considered the second highest level
of evidence on the scale, followed by systematic reviews
andmeta-analyses of non-neutral comparison studies, but
only those that exclude the results of the individual newly
introduced methods or the otherwise preferred method.
Finally, results on the non-preferred methods from these
individual non-neutral studies are of the second lowest
level of evidence, followed by expert opinion and results
from non-neutral studies on preferred methods.
Conclusion
The appropriate design of clinical trials has been the sub-
ject of decades of research, the goal of which has been
to improve the quality and reliability of research find-
ings.We have described an analogy to this evidence-based
medicine in the field of methodological computational
statistics. We suggest that benchmark studies—a method
of assessment of statistical methods using real-world
datasets—may benefit from adopting concepts from EBM
towards the goal of more evidence-based statistical
research. In particular, we have discussed the applica-
tion of inclusion and exclusion criteria to the selection
of datasets, and the use of placebos, study protocols and
methods of protecting against bias as common concepts in
the clinical world which would be beneficial in the design
and interpretation of high-quality benchmark studies.
We applied some of these ideas in a recent bench-
mark study comparing random forest and logistic regres-
sion currently available as a technical report [35]. In this
study, we perform sample size calculations, clearly define
the set of candidate datasets and the inclusion criteria,
and report missing values transparently. Moreover, the
Boulesteix et al. BMCMedical ResearchMethodology  (2017) 17:138 Page 11 of 12
authors of the study are equally familiar with both con-
sidered methods and have conducted research projects on
both of them in the past, thus ensuring a high level of
neutrality.
The questions of whether the choice of statistical meth-
ods for real data analysis should be based on evidence
that is itself based on real-data and how this could
be achieved can obviously not be answered by single
authors. Our manuscript is meant to fuel discussion
on the paradigms and challenges faced in computa-
tional statistics and suggests first potential steps towards
more “evidence-based” statistical research rather than
offering clear-cut guidance. However, we feel that the
definition of inclusion criteria for datasets, a clear state-
ment on the handling of missing values and a care-
ful and fair-minded consideration of issues related to
the researcher’s varying levels of competence regarding
the compared methods should currently be the minimal
requirements for evidence-based statistical research—
requirements easily satisfied in practice and without
hidden danger.
Abbreviations
EBM: Evidence-based medicine; STRATOS: STRengthening analytical thinking
for observational studies
Acknowledgements
We thank Hannah Busen and Sarah Tegenfeldt for helping us to prepare the
manuscript and Berhard Haller and Willi Sauerbrei for valuable comments.
Funding
This project was supported by the Deutsche Forschungsgemeinschaft (DFG),
grant BO3139/2-3 to ALB.
Availability of data andmaterials
Not applicable (debate article that does not refer to data).
Authors’ contributions
ALB drafted the manuscript. ALB and AH developed the concept. All authors
contributed significantly to the manuscript. All authors read and approved the
final manuscript.





The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Institute for Medical Information Processing, Biometry and Epidemiology,
LMU Munich, Marchioninistr. 15, 81377 Munich, Germany. 2Institute of Medical
Statistics and Epidemiology, Technical University Munich, Ismaninger Str. 22,
81675 Munich, Germany.
Received: 18 May 2017 Accepted: 31 August 2017
References
1. Greenhalgh T, Howick J, Maskrey N. Evidence based medicine: a
movement in crisis? Br Med J. 2014;348:3725. doi:10.1136/bmj.g3725.
2. Sauerbrei W, Abrahamowicz M, Altman DG, Le Cessie S, Carpenter J.
Strengthening analytical thinking for observational studies: the STRATOS
initiative. Stat Med. 2014;33(30):5413–432. doi:10.1002/sim.6265.
3. Lichman M. UCI Machine Learning Repository. 2013. http://archive.ics.uci.
edu/ml. Accessed 6 Sept 2017.
4. Vanschoren J, van Rijn JN, Bischl B, Torgo L. OpenML: Networked science
in machine learning. SIGKDD Explor. 2013;15(2):49–60.
doi:10.1145/2641190.2641198.
5. In: Guyon I, Cawley G, Dror G, editors. Hands-On Pattern Recognition:
Challenges in Machine Learning, Volume 1: MICROTOME PUB, Brookline,
Massachusetts; 2011. https://www.amazon.com/Hands-Pattern-
Recognition-Challenges-Learning/dp/0971977712.
6. Boulesteix AL, Hornung R, Sauerbrei W. On fishing for significance and
statistician’s degree of freedom in the era of big molecular data In:
Wernecke J, Pietsch W, Otte M, editors. Berechenbarkeit der Welt?
Philosophie und Wissenschaft Im Zeitalter Von Big Data. Springer VS;
2017. p. 155–170.
7. Silberzahn R, Uhlmann EL. Crowdsourced research: Many hands make
tight work. Nature. 2015;526(7572):189–91. doi:10.1038/526189a.
8. Ioannidis JPA. Why most published research findings are false. PLoS Med.
2005;2(8):124. doi:10.1371/journal.pmed.0020124.
9. Boulesteix AL, Hable R, Lauer S, Eugster MJA. A statistical framework for
hypothesis testing in real data comparison studies. Am Stat. 2015;69(3):
201–12. doi:10.1080/00031305.2015.1005128.
10. Boulesteix AL, Strobl C, Augustin T, Daumer M. Evaluating microarray-based
classifiers: an overview. Cancer Informat. 2008;6:77–97.
11. Dudoit S, Fridlyand J, Speed TP. Comparison of discrimination methods
for the classification of tumors using gene expression data. J Am Stat
Assoc. 2002;97(457):77–87.
12. Romualdi C, Campanaro S, Campagna D, Celegato B, Cannata N, Toppo S,
Valle G, Lanfranchi G. Pattern recognition in gene expression profiling
using dna array: a comparative study of different statistical methods
applied to cancer classification. Hum Mol Genet. 2003;12:823–36.
13. Li T, Zhang C, Ogihara M. A comparative study of feature selection and
multiclass classification methods for tissue classification based on gene
expression. Bioinformatics. 2004;20:2429–37.
14. Statnikov A, Aliferis CF, Tsamardinos I, Hardin D, Levy S. A comprehensive
evaluation of multicategory classification methods for microarray gene
expression cancer diagnosis. Bioinformatics. 2005;21(5):631–43.
15. Lee JW, Lee JB, Park M, Song SH. An extensive comparison of recent
classification tools applied to microarray data. Comput Stat Data Anal.
2005;48(4):869–85.
16. Huang X, Pan W, Grindle S, Han X, Chen Y, Park S, Miller L, Hall J.
A comparative study of discriminating human heart failure etiology using
gene expression profiles. BMC Bioinforma. 2005;6:205.
17. Statnikov A, Wang L, Aliferis C. A comprehensive comparison of random
forests and support vector machines for microarray-based cancer
classification. BMC Bioinforma. 2008;9:319.
18. de Souza BF, de Carvalho A, Soares C. A comprehensive comparison of
ml algorithms for gene expression data classification. In: The 2010 Inte
rnational Joint Conference on Neural Networks (IJCNN). IEEE; 2010. p. 1–8.
http://ieeexplore.ieee.org/document/5596651/?reload=true.
19. Boulesteix AL, Lauer S, Eugster MJA. A plea for neutral comparison
studies in computational sciences. PLoS ONE. 2013;8:61562.
doi:10.1371/journal.pone.0061562.
20. Hornung R, Boulesteix AL, Causeur D. Combining location-and-scale
batch effect adjustment with data cleaning by latent factor adjustment.
BMC Bioinforma. 2016;17:27. doi:10.1186/s12859-015-0870-z.
21. Fernández-Delgado M, Cernadas E, Barro S, Amorim D. Do we need
hundreds of classifiers to solve real world classification problems. J Mach
Learn Res. 2014;15(1):3133–81.
22. Yousefi MR, Hua J, Sima C, Dougherty ER. Reporting bias when using
real data sets to analyze classification performance. Bioinformatics.
2010;26(1):68–76. doi:10.1093/bioinformatics/btp605.
23. Rennie D. CONSORT revised—improving the reporting of randomized
trials. JAMA. 2001;285(15):2006–7. doi:10.1001/jama.285.15.2006.
24. Boulesteix AL, Stierle V, Hapfelmeier A. Publication bias in methodological
computational research. Cancer Informat. 2015;14(Suppl 5):11–19.
doi:10.4137/CIN.S30747.
Boulesteix et al. BMCMedical ResearchMethodology  (2017) 17:138 Page 12 of 12
25. De Angelis C, Drazen JM, Frizelle FA, Haug C, Hoey J, Horton R, Kotzin S,
Laine C, Marusic A, Overbeke AJP, et al. Clinical trial registration: a
statement from the international committee of medical journal editors.
N Engl J Med. 2004;351(12):1250–51.
26. Chambers CD. Registered reports: A new publishing initiative at Cortex
[editorial]. Cortex. 2013;49(3):609–10.
27. Jelizarow M, Guillemot V, Tenenhaus A, Strimmer K, Boulesteix AL.
Over-optimism in bioinformatics: an illustration. Bioinformatics.
2010;26(16):1990–8. doi:10.1093/bioinformatics/btq323.
28. Binder H, Sauerbrei W, Royston P. Comparison between splines and
fractional polynomials for multivariable model building with continuous
covariates: a simulation study with continuous response. Stat Med.
2013;32(13):2262–77.
29. Bischl B, Schiffner J, Weihs C. Benchmarking local classification methods.
Comput Stat. 2013;28(6):2599–619. doi:10.1007/s00180-013-0420-y.
30. Duin RP. A note on comparing classifiers. Pattern Recogn Lett. 1996;17(5):
529–36.
31. Canadian Task Force on the Periodic Health Examination. The periodic
health examination. Can Med Assoc J. 1979;121(9):1193–54.
32. Boulesteix AL. On representative and illustrative comparisons with real
data in bioinformatics: response to the letter to the editor by smith et al.
Bioinformatics. 2013;29(20):2664–6.
33. Jamain A, Hand DJ. Mining supervised classification performance studies:
Ameta-analytic investigation. J Classif. 2008;25(1):87–112. doi:10.1007/s003
57-008-9003-y.
34. Sargent DJ. Comparison of artificial neural networks with other statistical
approaches: results from medical data sets. Cancer. 2001;91:1636–42.
35. Couronné R, Probst P, Boulesteix AL. Random forest versus logistic
regression: a large-scale benchmark experiment. 2017. Technical Report
205, Department of Statistics, LMU Munich.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
